15 to 16 December 2015

NICE, Level 1a, City Tower, Piccadilly Plaza, Manchester

Please note that this agenda is subject to change prior to the meeting.

Final Agenda – Tuesday 15 December 2015

The meeting will start promptly at 10.00 and is expected to finish at approximately 17.00

  1. Welcome and introductions - Part 1 only (open session)
  2. Code of Conduct for members of the public attending the meeting - Part 1 only (open session)
  3. Declarations of Interest – Part 1 only (open session)
  4. Objectives of the day - Part 1 only (open session)
  5. Topic: ADHD update
    1. Responses to stakeholder consultation - Part 1 only (open session)
  6. Topic: Psychosis & schizophrenia in children & young people
      1. Introduction to the topic – Part 1 only (open session)
      2. Committee questions to topic experts – Part 1 only (open session)
      3. Review and discussion of the clinical and health economic evidence – Part 1 only (closed session
        1. What is the adverse effects profile of olanzapine compared to other second-generation antipsychotics (SGAs) for treating children and young people with psychosis and schizophrenia?
      4. Equalities impact assessment – Part 1 only (closed session
      5. Draft recommendations – Part 2 only (closed session)

7. Reflections, next steps and AOB – Part 1 only (open session)

Close of meeting

 

Please note that this agenda is subject to change prior to the meeting.

Final Agenda – Wednesday 16 December 2015

The meeting will start promptly at 09.45 and is expected to finish at approximately 17.00

  1. Welcome and introductions - Part 1 only (open session)
  2. Code of Conduct for members of the public attending the meeting - Part 1 only (open session)
  3. Declarations of Interest – Part 1 only (open session)
  4. Objectives of the day - Part 1 only (open session)
  5. Topic: Crohn’s
      1. Introduction to the topic – Part 1 only (open session)
      2. Committee questions to topic experts – Part 1 only (open session)
      3. Review and discussion of the clinical and health economic evidence –
        1. What is the clinical and cost-effectiveness of TNF alpha inhibitor biologics (infliximab and adalimumab) in combination with immunosuppressants compared with infliximab or adalimumab alone?
      4. Equalities impact assessment
      5. Draft recommendations – Part 2 only (closed session)
  1. Reflections, next steps and AOB – Part 1 only (closed session)

Close of meeting

 

Please note all timings are approximate.

Date, time and venue of next meeting

17 March 2016, NICE offices, 10 Spring Gardens, London, SW1A 2BU

To print this agenda, please right click and select ‘Print’ from the menu

To register

You will receive an automated email response when you submit the registration form. If you do not receive this automated response your registration request has not been received, and you will need to complete and submit the registration form again.

The closing date for registration is 01 Decemeber 2015. Please note that it may not be possible to accept late registration requests.

Should you have queries regarding attending this meeting, please contact the Meetings in Public Coordinator Lee Berry

Please note that registrants wishing to conduct a research study on the committee meeting and/or NICE processes will require prior permission and should contact NICE Enquiry Handling by email Nice@nice.org.uk further information about conducting research is also available in our Common Questions and Answers about meetings in public document.

 

Registration period: 17 November 2015 to 01 December 2015
Registration is closed.